Tesofensine side effects by evidence tier: the dose-dependent heart-rate and blood-pressure rise, dry mouth, insomnia and mood signals from the Phase 2 and 3 trials, and the gaps.
"Tesofensine side effects" is unusual among searches on this site in having a real answer: the compound has been through randomised, placebo-controlled human trials, and its adverse-event profile is characterised — for courses of 14 to 24 weeks, in one sponsor's hands, in participants screened to exclude the people most at risk from it. This page keeps those qualifications attached, separates trial data from inference and self-report, and lists the gaps. It is a research reference, not medical advice; the Tesofensine profile is the reference entry and the tesofensine research overview covers the development history.
The primary source is TIPO-1 (Astrup and colleagues, The Lancet, 2008), which randomised 203 obese adults to placebo or 0.25, 0.5 or 1.0 mg tesofensine once daily for 24 weeks on a hypocaloric diet. The most common adverse events were dry mouth, nausea, constipation, hard stools, diarrhoea and insomnia, all dose-related. Mood changes, including agitation and irritability, were reported at the higher doses. Dry mouth and insomnia are what the noradrenergic and dopaminergic components of the mechanism predict.
The signal that shaped the programme is cardiovascular. Heart rate rose by roughly seven to eight beats per minute at the 0.5 and 1.0 mg doses, and the 1.0 mg dose raised blood pressure significantly. The sponsor dropped 1.0 mg and took 0.25 and 0.5 mg into the Mexican Phase 3 programme, whose top-line results Saniona has reported as positive; its full safety dataset has not been published in a form this page can quote. The mechanistic study by Sjödin and colleagues (International Journal of Obesity, 2010), at 2.0 mg daily for 14 days, saw the same heart-rate effect.
Two facts frame it. First, the sponsor built a second product, Tesomet, pairing 0.5 mg tesofensine with 50 mg of the beta-blocker metoprolol specifically to blunt the heart-rate increase — its own acknowledgement that the signal is real and dose-limiting. Second, sibutramine — a noradrenaline–serotonin reuptake inhibitor and tesofensine's weaker relative — was withdrawn worldwide in 2010 after a large outcome trial showed excess cardiovascular events. Tesofensine has no long-term cardiovascular-outcome data at all. That is not a finding of harm; it is the single largest gap in the record, and a measured heart-rate rise cannot be assumed benign because the trials were too short to test what it leads to. The neurological trials — early Parkinson's disease (2007), ADVANS (Rascol and colleagues, Archives of Neurology, 2008) and the Alzheimer's studies at 0.125–1.0 mg daily over 14 weeks — were negative on efficacy and are the source of the pharmacokinetic data.
Tesofensine raises synaptic dopamine as well as noradrenaline and serotonin, which distinguishes it from sibutramine and is why the abuse-liability question has been raised. Its slow onset and nine-day half-life make the pharmacology quite unlike a stimulant taken for effect, but that is a pharmacokinetic argument, not a demonstration, and no abuse-liability study is on file here. What the trials recorded is insomnia and, at higher doses, agitation and irritability. Serotonin reuptake inhibition adds a theoretical risk of serotonin syndrome with SSRIs, SNRIs, tramadol, triptans and MAO inhibitors; the noradrenergic and dopaminergic actions are additive with any sympathomimetic on heart rate and blood pressure. The trials excluded participants taking such medicines, so the interaction risk is inferred from mechanism, not measured.
Population pharmacokinetic modelling (Lehr and colleagues, British Journal of Clinical Pharmacology, 2007) estimated a half-life of about 220 hours — nine days — for tesofensine and longer for its active metabolite NS2360. Two consequences follow. Steady state takes five to six weeks, so an adverse effect absent in the first fortnight says little about the exposure the trials studied. And elimination is equally slow: an adverse effect, or an interaction, persists for weeks after the last dose and cannot be reversed quickly by stopping. The half-life calculator plots both the accumulation and the washout for the 220-hour figure.
The published record supports a narrow statement — dose-dependent sympathomimetic and gastrointestinal effects and a consistent heart-rate rise over 14–24 weeks in screened trial populations — and nothing broader. There is no controlled human safety data for:
Community and vendor reports describe the same dry mouth, insomnia and raised resting heart rate, plus anxiety. They are uncontrolled self-reports with no denominator and cannot establish incidence, causation or severity.
Tesofensine is a small molecule, so the analytical picture is purity by HPLC and identity by mass spectrometry or NMR on a certificate of analysis — see lab testing and COAs. Two confounds are specific to it. It is potent at sub-milligram amounts, so a weighing or dilution error is proportionally enormous, and an apparent "side effect" in a laboratory setting may be a dose error. And it is usually handled as a salt; a certificate that does not state which form it reports leaves the mass ambiguous. Neither confound exists in a pharmaceutical tablet.
Tesofensine has no market authorisation from Health Canada, no Drug Identification Number, and no FDA or EMA approval; the sponsor's regulatory effort has been directed at Mexico. It is not scheduled under the Controlled Drugs and Substances Act and is sold in Canada, as on the tesofensine product page, for laboratory research only. It is not named on the WADA Prohibited List, but the S6 stimulant category prohibits substances with a similar structure or biological effect to those listed, and a dopamine–noradrenaline reuptake inhibitor may fall under it; tested athletes should treat it as prohibited until their anti-doping organisation says otherwise.
What side effects did the tesofensine trials report? Dry mouth, nausea, constipation, hard stools, diarrhoea and insomnia, all dose-related, with agitation and irritability at higher doses. Heart rate rose about seven to eight beats per minute at 0.5 and 1.0 mg, and 1.0 mg raised blood pressure significantly.
Why was the 1.0 mg dose dropped? It produced a significant rise in blood pressure for roughly one extra percentage point of weight loss over 0.5 mg. The sponsor carried only 0.25 and 0.5 mg into Phase 3 and later paired the compound with metoprolol in Tesomet to counter the heart-rate effect.
Does the heart-rate increase matter? No outcome trial has tested it. The precedent is sibutramine, a weaker relative withdrawn in 2010 after excess cardiovascular events in a large trial; the absence of long-term outcome data is the largest gap in tesofensine's safety record.
How long do effects persist after the last dose? Weeks. The half-life is about 220 hours, so both effects and adverse effects wash out slowly, and a drug interaction begun during a course persists long after it ends.
Is this medical advice? No. This page reports the published adverse-event literature for researchers. Tesofensine is not for human or veterinary use; any health decision belongs with a qualified physician.
